Blueprint Medicines (BPMC) Stock Price, News & Analysis

Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $129.46 to $129.46
• 50-Day Range: $127.95 to $129.48
• 52-Week Range: $73.04 to $129.65
• Volume: N/A
• Average Volume: 1.55 million shs
• Market Capitalization: $8.36 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $130.00
• Consensus Rating: Hold

BPMC Stock Analysis - Frequently Asked Questions

How have BPMC shares performed this year?

Blueprint Medicines' stock was trading at $87.22 at the start of the year. Since then, BPMC stock has increased by 48.4% and is now trading at $129.46.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Corporation (NASDAQ:BPMC) released its quarterly earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.32. Blueprint Medicines's quarterly revenue was up 55.5% on a year-over-year basis.
Read the conference call transcript.

When did Blueprint Medicines IPO?

Blueprint Medicines (BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' top institutional investors include State Street Corp (3.45%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.65%), Geode Capital Management LLC (2.39%) and Norges Bank (1.66%). Insiders that own company stock include Kate Haviland, Jeffrey W Albers, Fouad Namouni, Christina Rossi, Tracey L Mccain, Percy H Carter, Michael Landsittel, Debra Durso-Bumpus, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley.
View institutional ownership trends.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 8/15/2025
• Next Earnings (Estimated): 10/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BPMC
• CIK: 1597264
• Web: www.blueprintmedicines.com
• Phone: (617) 374-7580
• Fax: N/A
• Employees: 640
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Blueprint Medicines: $130.00
• High Price Target: $135.00
• Low Price Target: $119.00
• Potential Upside/Downside: +0.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.11
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.09 million
• Net Margins: -27.70%
• Pretax Margin: -27.38%
• Return on Equity: -64.60%
• Return on Assets: -17.22%

Debt

• Debt-to-Equity Ratio: 1.01
• Current Ratio: 2.80
• Quick Ratio: 2.75

Sales & Book Value

• Annual Sales: $562.12 million
• Price / Sales: 14.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.70 per share
• Price / Book: 27.54

Miscellaneous

• Outstanding Shares: 64,582,000
• Free Float: 61,863,000
• Market Cap: $8.36 billion
• Optionable: Optionable
• Beta: 0.89